Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

KRX/128940 stock hub

KRX/128940 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KRX/128940is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

5.5T

Korea Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

KRX/128940

In the news

Latest news · KRX/128940

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E29.5

P25 9.8P50 17.1P75 31.9

Trailing P/E32.6

P25 12P50 23.1P75 39.5

ROE14.1

P25 -17.1P50 0.7P75 8.5

ROIC12.2

P25 -9P50 1.3P75 6.8

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KRX/128940 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

239

Groups with data

Currency

KRW

Showing 239 of 239 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	South Korea
Country code	KR
Employees	2,400
Enterprise value	KRW 5.9T
Exchange	Korea Stock Exchange
Financial currency	KRW
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	KR7128940004
Last refreshed	2026-05-10
Market cap	KRW 5.5T
Price	KRW 436,000
Price currency	KRW
Rev Per Employee	644,804,624.48x
Sector	Healthcare
Sic	2834
Symbol	krx/128940
Website	https://www.hanmipharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.07%
EV Earnings	35x
EV/EBIT	26.51x
EV/EBITDA	18.39x
EV/FCF	45.63x
EV/Sales	3.83x
FCF yield	2.35%
Forward P/E	29.52x
P/B ratio	3.89x
P/E ratio	32.63x
P/S ratio	3.57x
PE Ratio10 Y	107.39x
PE Ratio3 Y	30.03x
PE Ratio5 Y	48.27x
PEG ratio	1.34x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	14.47%
EBITDA Margin	20.85%
FCF margin	8.4%
Gross margin	57.15%
Gross Profit	KRW 884.4B
Gross Profit Growth	8.25%
Gross Profit Growth Q	40.62%
Gross Profit Growth3 Y	7.17%
Gross Profit Growth5 Y	8.77%
Net Income	KRW 169.6B
Net Income Growth	39.76%
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Net Income Growth3 Y	26.99%
Net Income Growth5 Y	69.95%
Pretax Margin	13.79%
Profit Margin	10.96%
Profit Per Employee	KRW 70.6M
Profitable Years	15
ROA	6.73
Roa5y	5.99
ROCE	14.61
ROE	14.05
Roe5y	12.29
ROIC	12.22
Roic5y	10.58

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-0.47%
Cagr15y	14.9%
Cagr1y	70%
Cagr3y	10.87%
Cagr5y	6.6%
Div CAGR10	16.24%
Div CAGR3	58.74%
Div CAGR5	33%
EPS Growth	39.67
EPS Growth Quarters	3
EPS Growth Years	1
EPS Growth3 Y	27.04
EPS Growth5 Y	70.07
FCF Growth	-15.68%
FCF Growth Q	84.45%
FCF Growth3 Y	-0.47%
FCF Growth5 Y	3.46%
OCF Growth	-10.55%
OCF Growth Q	-1.68%
OCF Growth10 Y	5.46%
OCF Growth3 Y	2.17%
OCF Growth5 Y	2.69%
Revenue Growth	3.48x
Revenue Growth Q	23.14x
Revenue Growth Quarters	3x
Revenue Growth Years	5x
Revenue Growth3 Y	5.14x
Revenue Growth5 Y	7.54x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	KRW 0.74
Assets	KRW 2.1T
Cash	KRW 201.3B
Current Assets	KRW 893.9B
Current Liabilities	KRW 605.2B
Debt	KRW 434.2B
Debt EBITDA	KRW 1.35
Debt Equity	KRW 0.31
Debt FCF	KRW 3.34
Equity	KRW 1.4T
Interest Coverage	13.18
Liabilities	KRW 714.7B
Long Term Assets	KRW 1.2T
Long Term Liabilities	KRW 109.5B
Net Cash	KRW -232.9B
Net Cash By Market Cap	KRW -4.21
Net Debt EBITDA	KRW 0.72
Net Debt Equity	KRW 0.16
Net Debt FCF	KRW 1.79
Tangible Book Value	KRW 1.2T
Tangible Book Value Per Share	KRW 94,552
WACC	6.39

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.48
Inventory Turnover	2.07
Net Working Capital	KRW 424.9B
Quick ratio	0.9
Working Capital	KRW 288.7B
Working Capital Turnover	KRW 8.79

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.07%
Dividend Growth	0%
Dividend Growth Years	7%
Dividend per share	KRW 1,250
Dividend Years	1
Dividend Yield	0.29%
Ex Div Date	2026-03-30
Last Dividend	KRW 2,000
Payout Frequency	Annual
Payout Ratio	18.2%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-4.6%
1Y total return	69.94%
200-day SMA	425,097.5
3Y total return	36.28%
50-day SMA	509,550
50-day SMA vs 200-day SMA	50over200
5Y total return	37.66%
All Time High	699,536
All Time High Change	-37.67%
All Time High Date	2015-11-10
All Time Low	34,727.5
All Time Low Change	1,155.49%
All Time Low Date	2012-05-24
ATR	22,377.8
Beta	0.43
Beta1y	0.4
Beta2y	0.65
Ch YTD	-3.54
High	440,000
High52	647,000
High52 Date	2026-02-24
High52ch	-32.61%
Low	431,000
Low52	258,500
Low52 Date	2025-05-12
Low52ch	68.67%
Ma50ch	-14.43%
Price vs 200-day SMA	2.56%
RSI	33.01
RSI Monthly	56.43
RSI Weekly	44.9
Sharpe ratio	1.24x
Sortino ratio	2.18
Total Return	0.22%
Tr YTD	-3.19
Tr15y	702.72%
Tr1m	-14%
Tr1w	-2.02%
Tr3m	-20.73%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	KRW 223.9B
Operating Income Growth	5.35
Operating Income Growth Q	104.4
Operating Income Growth3 Y	13.31
Operating Income Growth5 Y	35.52
Operating margin	14.47

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6,262,265%
Net Borrowing	-66,334,239,400
Shares Insiders	7.81%
Shares Institutions	19.25%
Shares Out	12,680,214
Shares Qo Q	0.28%
Shares Yo Y	0.07%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	KRW 130B
Average Volume	87,140.45x
Bv Per Share	98,559.6
CAPEX	KRW -43B
Ch10y	-6.31
Ch15y	669.9
Ch1m	-14
Ch1w	-2.02
Ch1y	69.32
Ch3m	-21.01
Ch3y	34.97
Ch5y	35.88
Ch6m	-0.68
Change	1.28%
Change From Open	0.23
Close	430,500
Days Gap	1.05
Depreciation Amortization	98,808,984,620
Dollar Volume	25,941,564,000
Earnings Date	2026-04-30
EBIT	KRW 223.9B
EBITDA	KRW 322.7B
EPS	KRW 13,362
F Score	6
FCF	KRW 130B
FCF EV Yield	2.19x
FCF Per Share	KRW 10,256
Financing CF	-97,189,636,030
Fiscal Year End	December
Founded	1,973
Graham Number	172137.8481
Graham Upside	-60.52
Income Tax	KRW 26.3B
Investing CF	-159,455,090,140
Is Primary Listing	1
Last Earnings Date	2026-04-30
Last Report Date	2025-12-31
Last Split Date	2023-12-27
Last Split Type	Forward
Lynch Fair Value	KRW 334,050
Lynch Upside	-23.38
Ma150	468,850
Ma150ch	-7.01%
Ma20	488,050
Ma20ch	-10.66%
Net CF	-84,003,716,090
Open	435,000
P FCF Ratio	42.51
P OCF Ratio	31.94
Payment Date	2026-04-17
Position In Range	55.56
Ppne	786,291,897,470
Price Date	2026-05-08
Price EBITDA	KRW 17.13
Ptbv Ratio	4.61
Relative Volume	0.68x
Revenue	1,547,531,098,750x
Tax By Revenue	1.7x
Tax Rate	12.34%
Tr6m	-0.32%
Volume	59,499
Z Score	5.1

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

KRX/128940 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.3%

$1250 annual per share

Payout ratio

+18.2%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+33.0%

7 consecutive years of growth

Total shareholder yield

+0.2%

Next ex-dividend date: 2026-03-30

Performance

KRX/128940 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KRX/128940?

Insider, institutional, and short-interest positioning.

Institutional ownership

+19.2%

Share of float held by funds and institutions

Insider ownership

+7.8%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.1%

Negative means the company is buying back shares.

Technical

KRX/128940 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

33.0

Neutral momentum band

Price vs 200-day MA

+2.6%

50/200-day relationship not available

Beta (5Y)

0.43

Less volatile than the market

Sharpe ratio

1.24

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KRX/128940

Hub-level FAQ points readers to the deeper analysis pages.

What is the current krx/128940 stock rating?

krx/128940 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full krx/128940 analysis?

The full report lives at /stocks/krx/128940/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for krx/128940?

The latest report frames krx/128940 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the krx/128940 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.